IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Johanna Mondesir1,2 Christophe Willekens3–5 Mehdi Touat6,7 Stéphane de Botton3–5 1Service d’Immunopathologie Clinique, Hôpital Saint Louis, 2CNRS UMR8104, INSERM U1016, Institut Cochin, Université Paris Descartes, Paris, 3Gustave Roussy,...

Full description

Bibliographic Details
Main Authors: Mondesir J, Willekens C, Touat M, de Botton S
Format: Article
Language:English
Published: Dove Medical Press 2016-09-01
Series:Journal of Blood Medicine
Subjects:
Tumor metabolism
epigenetic
oncogene
IDH1
IDH2
glioma
acute myeloid leukemia
2-HG
targeted therapies.
Online Access:https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM

Internet

https://www.dovepress.com/idh1-and-idh2-mutations-as-novel-therapeutic-targets-current-perspecti-peer-reviewed-article-JBM

Similar Items